Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/ hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 4, 2012, Pages 269-276

  Kielbasa, William ^a   Quinlan, Tonya ^a   Jin, Ling ^a   Xu, Wen ^a   Lachno, D Richard ^a   Dean, Robert A ^a   Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDIVOXETINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIQUID CHROMATOGRAPHY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; AGE FACTORS; AREA UNDER CURVE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; MALE; MORPHOLINES; PHENYLETHYL ALCOHOL; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84865242835     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0151     Document Type: Article

References (19)

1. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW: Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 42:1219-1227, 2002. (Pubitemid 35205057)
2. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711, 2002. (Pubitemid 35335888)
3. Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, Hirth C, Potter WZ: Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, controlled study. Neuropsychopharmacology 28:1685-1693, 2003. (Pubitemid 41070869)
4. Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095, 1993. (Pubitemid 23211439)
5. Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P: A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res 44:356-363, 2010.
6. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Press; 1998.
7. Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ: Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32:2030-2033, 1986.
8. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: US Department of Health, Education, and Welfare; 1976.
9. Jin L, Xu W, Kielbasa W, Quinlan T, Kauffman L, Allen AJ: Safety and efficacy of edivoxetine in an open-label study in pediatric patients with attention-deficit/hyperactivity disorder. Poster presented at American Academy of Child & Adolescent Psychiatry Annual Meeting, New York, 2011.
10. Kielbasa W, Bingham J, Bieck P: Pharmacokinetic-pharmacodynamic modeling of atomoxetine in adults: Characterization of dihydroxyphenylglycol (DHPG), a pharmacological marker of norepinephrine transport (NET) inhibition, in plasma and cerebrospinal fluid. Poster presented at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition, San Antonio, TX, 2006. Abstract available at: www.aapsj.org/abstracts/ AM-2006/AAPS2006-002685.pdf Kielbasa W, Luffer-Atlas D, Wondmagegnehu E, Mitchell M, Turik M: Investigation of the potential for PK interactions between edivoxetine, a norepinephrine reuptake inhibitor, and selective serotonin reuptake inhibitor antidepressants in humans. Poster presented at American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Dallas, 2011.
11. Kielbasa W, Quinlan T, Lachno R, Bredt D, Dube S: Pharmacodynamics of LY2216684: Evaluation of peripheral and central norepinephrine transporter inhibition using 3,4-dihydroxyphenylglycol as a biomarker of pharmacologic activity. Neuropsychopharmacology 35:S390, 2010 (poster).
12. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:E83, 2001.
13. Montoya A, Escobar R, Garci'a-Polavieja MJ, Lachno DR, Alda JÁ, Artigas J, Cardo E, Garci'a M, Gastaminza X, Gilaberte I: Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine. J Child Neurol 26:31-36, 2011.
14. Pangallo B, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C: A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 45:748-755, 2011.
15. Popper CW: Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:605-646, 2000. (Pubitemid 30620546)
16. Quinlan T, KielbasaW: Population pharmacokinetic/pharmacodynamic modeling and simulations of the effect of edivoxetine on heart rate and the norepinephrine metabolite, 3, 4-dihydroxyphenylglycol (DHPG), in plasma and cerebrospinal fluid (CSF). Poster presented at American Conference of Pharmacometrics, San Diego, CA, 2011.
17. Quinlan T, Knadler MP, Pangallo B, Chappell J, Lobo E: Pharmacokinetic/pharmacodynamic modeling of the effects of duloxetine on 3,4-dihydroxyphenylglycol (DHPG) in plasma and cerebrospinal fluid in healthy subjects. Poster presented at American Conference on Pharmacometrics, Mashantucket, CT, 2009.
18. Sauer JM, Ring BJ, Witcher JW: Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44:571-590, 2005. (Pubitemid 40994086)
19. Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D: Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 109:3202-3207, 2004.